Our Development Pipeline
TMB-001 (topical isotretinoin) is being developed for the treatment of moderate to severe subtypes of CI. In a Phase 2a study, treatment with TMB-001 was shown to be well tolerated with no evidence of systemic absorption of isotretinoin. There was also a clear signal of efficacy in the study with patients showing a reduction in scaling after eight weeks. In 2018, the FDA awarded $1.5 million to support Phase 2a and Phase 2b clinical trials evaluating TMB-001 through its Orphan Products Grant program. Timber expects to enroll the first patient in a Phase 2b clinical trial in Q4 2019.
If you are interested in any of Timber’s ongoing clinical research programs, please contact firstname.lastname@example.org.